Cullinan Therapeutics, Inc.
CGEM
$9.07
$0.111.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.67% | 36.84% | 21.55% | 34.80% | 15.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.93% | 21.02% | 9.04% | 33.03% | -31.50% |
| Operating Income | -27.93% | -21.02% | -9.04% | -33.03% | 31.50% |
| Income Before Tax | -29.89% | -19.77% | -3.51% | -30.47% | 35.78% |
| Income Tax Expenses | -- | 100.83% | -- | -- | -- |
| Earnings from Continuing Operations | -29.89% | -86.39% | -3.51% | -30.47% | 35.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -- | -- | 7.26% |
| Net Income | -30.56% | -100.17% | -3.51% | -30.47% | 35.91% |
| EBIT | -27.93% | -21.02% | -9.04% | -33.03% | 31.50% |
| EBITDA | -27.98% | -21.06% | -9.07% | -33.11% | 31.54% |
| EPS Basic | 4.67% | -46.24% | 24.17% | 5.32% | 39.38% |
| Normalized Basic EPS | 4.37% | 5.83% | 23.31% | 5.32% | 39.46% |
| EPS Diluted | 4.67% | -46.24% | 24.17% | 5.32% | 39.38% |
| Normalized Diluted EPS | 4.37% | 5.83% | 23.31% | 5.32% | 39.46% |
| Average Basic Shares Outstanding | 36.95% | 36.89% | 36.51% | 37.80% | 5.72% |
| Average Diluted Shares Outstanding | 36.95% | 36.89% | 36.51% | 37.80% | 5.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |